Advice

in the absence of a submission from the holder of the marketing authorisation:

golimumab (SimponiĀ®) is not recommended for use within NHSScotland.

Indication under review: in combination with methotrexate for the treatment of polyarticular juvenile idiopathic arthritis in children 2 years of age and older who have responded inadequately to previous therapy with methotrexate.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.

Download detailed advice357KB (PDF)

Download

Medicine details

Medicine name:
golimumab (Simponi)
SMC ID:
SMC2203
Indication:
In combination with methotrexate for the treatment of polyarticular juvenile idiopathic arthritis in children 2 years of age and older who have responded inadequately to previous therapy with methotrexate.
Pharmaceutical company
Merck Sharp & Dohme Ltd
BNF chapter
Musculoskeletal and joint diseases
Submission type
Non submission
Status
Not recommended
Date advice published:
10 June 2019